[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.495, "dayLow": 1.17, "dayHigh": 1.9, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.495, "regularMarketDayLow": 1.17, "regularMarketDayHigh": 1.9, "beta": 0.264, "forwardPE": -0.06459446, "volume": 16128, "regularMarketVolume": 16128, "averageVolume": 63659, "averageVolume10days": 5350, "averageDailyVolume10Day": 5350, "bid": 1.22, "ask": 1.6, "askSize": 40000, "marketCap": 2135660, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 9.483, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.89236, "twoHundredDayAverage": 3.19028, "currency": "USD", "enterpriseValue": 10936665, "floatShares": 891857, "sharesOutstanding": 1605760, "sharesShort": 19195, "sharesShortPriorMonth": 10600, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012, "heldPercentInsiders": 0.53457, "heldPercentInstitutions": 0.113529995, "shortRatio": 0.19, "shortPercentOfFloat": 0.0276, "impliedSharesOutstanding": 1605760, "bookValue": 11.856, "priceToBook": 0.11217949, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -16283000, "trailingEps": -9.81, "forwardEps": -20.59, "lastSplitFactor": "1:30", "lastSplitDate": 1686528000, "enterpriseToEbitda": -0.487, "52WeekChange": -0.8310038, "SandP52WeekChange": 0.26238096, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "messageBoardId": "finmb_320858778", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.33, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 20762000, "totalCashPerShare": 12.93, "ebitda": -22464000, "totalDebt": 29563000, "quickRatio": 5.934, "currentRatio": 6.052, "debtToEquity": 155.284, "returnOnAssets": -0.21935, "returnOnEquity": -0.62639, "freeCashflow": -20337500, "operatingCashflow": -22486000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]